ASCENTAGE-B(06855) announced multiple clinical advancements at the 2026 European Hematology Association (EHA) annual meeting.

The 17 clinical developments of the company's core products have been unveiled at the 2026 European Hematology Association (EHA) Annual Meeting, including 8 poster presentations. The showcased data involves the company's two major products - China's first marketed third-generation BCR-ABL inhibitor, oleritibinib (trade name: Nariten; development code: HQP1351) and China's first marketed domestically developed Bcl-2 selective inhibitor, lisatoclacra (trade name: Lishengtu; development code: APG-2575), fully demonstrating the company's deep layout and global innovative strength in the field of hematologic tumors. The 2026 European Hematology Association (EHA) Annual Meeting was held in Stockholm, Sweden from June 11, 2026 to June 14, 2026. At this year's EHA Annual Meeting, oleritibinib presented key evidence-based data updates in the dual treatment fields of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): in the CML field, oleritibinib has shown persistent and deep treatment effects for first-line TKI-resistant and/or intolerant CML chronic phase (CML-CP) patients without the T315I mutation, showing strong potential for second-line treatment; for CML-CP patients who have failed treatment with at least 2 TKIs, oleritibinib can be used as a standard treatment; at the same time, positive clinical data is shown for the product targeting CML patients resistant to multiple TKIs and with high-risk gene mutations. In the Ph+ ALL field, oleritibinib continues to demonstrate robust efficacy, with the global registration phase III data (POLARIS-1) further validating its excellent deep remission rate and safety controllability; and in subpopulations such as children with relapsed/refractory Ph+ ALL, impressive clinical data was obtained with the non-chemotherapy combination regimen of lisatoclacra. Lisatoclacra provided an update on the phase II registration data targeting chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), providing important references for refining drug strategies for different populations and optimizing individualized dosing regimens through baseline characteristics and prognostic-related stratified analysis. Real-world data on lisatoclacra in myeloid tumors also provided strong evidence for its clinical value.